KLOW Blend Protocol
KLOW is a fixed four-peptide research blend — GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg in a single 80 mg vial — combining copper-mediated regeneration, tissue repair, cell-migration, and anti-inflammatory pathways studied individually across its four components.
1What's in the vial
KLOW is a fixed blend — the four peptides are lyophilized together in one vial, so you cannot dose them separately. The mass ratio is always 50 : 10 : 10 : 10 (GHK-Cu is 62.5% of the total).
2Reconstitute & dose
Because the ratio is fixed, every draw delivers all four peptides proportionally — you dose the blend, not one peptide. The calculator below shows exactly how many mg of each peptide any draw delivers. Anchor your draw to whichever component you're studying (most researchers anchor to GHK-Cu, the 62.5% majority, or to the BPC-157 / TB-500 tissue-repair range).
A few common reconstitution points for the 80 mg vial (BAC water = bacteriostatic water):
These are arithmetic examples of what a draw delivers at a given reconstitution — not dose recommendations. Use the calculator to model your own vial and draw.
3Administration & storage
Route. In research practice KLOW is administered subcutaneously with a U-100 insulin syringe. (GHK-Cu on its own is also studied topically, but the blend is reconstituted and injected.)
Storage. Store the lyophilized vial cold and protected from light; once reconstituted with bacteriostatic water, refrigerate (2–8 °C) and use within the BAC water's preservative window. GHK-Cu is copper-blue in solution — a faint blue tint after reconstitution is expected.
4What each peptide is studied for
GHK-Cu 50 mg
Copper-binding tripeptide; the best-characterized component. Studied for skin remodeling, wound signaling, and antioxidant gene expression.
BPC-157 10 mg
Gastric pentadecapeptide studied in preclinical models for tissue, tendon, and gut-barrier repair.
TB-500 10 mg
Thymosin β4 fragment studied for actin regulation, cell migration, and soft-tissue repair.
KPV 10 mg
C-terminal α-MSH tripeptide (Lys-Pro-Val) studied for anti-inflammatory signaling.
5Evidence
No study evaluates the four-peptide blend together; the evidence base is the individual components' preclinical literature:
- Pickart 2015 — GHK-Cu review (PMID 26236730)
- He et al. 2022 — Pharmacokinetics, distribution, metabolism, and excretion of BPC 157 in rats and dogs, Front Pharmacol (PMID 36588717)
- Sikiric et al. 2018 — Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157: Vascular Recruitment and Gastrointestinal Tract Healing, Curr Pharm Des (PMID 29879879)
- Crockford et al. 2010 — Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications, Ann N Y Acad Sci (PMID 20536467)
6Regulatory & safety
Related tools
Add bacteriostatic water to the lyophilized 80mg vial. For example, 2 mL of BAC water gives a total-blend concentration of 40 mg/mL; a 5-unit (0.05 mL) draw then delivers roughly GHK-Cu 1.25 mg, BPC-157 250 mcg, TB-500 250 mcg, and KPV 250 mcg.
Frequently Asked Questions
KLOW is a fixed four-peptide blend in one 80mg vial: GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg, and KPV 10mg (a 5:1:1:1 mass ratio).
No validated human dose exists for the blend. In research practice the 80mg vial is reconstituted with bacteriostatic water and administered subcutaneously. Because the ratio is fixed, every draw delivers all four peptides proportionally — GHK-Cu is 62.5% of any draw. Use the reconstitution calculator to see the exact mg of each peptide per draw.
Add bacteriostatic water to the lyophilized 80mg vial. For example, 2 mL of BAC water gives a total-blend concentration of 40 mg/mL; a 5-unit (0.05 mL) draw then delivers roughly GHK-Cu 1.25 mg, BPC-157 250 mcg, TB-500 250 mcg, and KPV 250 mcg.